SHIM
PCRX icon

Stone House Investment Management’s Pacira BioSciences PCRX Stock Holding History

Stone House Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.96K Buy
156
+54
+53% +$1.28K ﹤0.01% 608
2026
Q1 		$2.31K Buy
+102
New +$2.27K ﹤0.01% 574

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stone House Investment Management's PCRX Position: Q2 2026 in Review

Stone House Investment Management increased its Pacira BioSciences (PCRX) stake by 53% in Q2 2026, buying an estimated $1.28K and bringing the position to 156 shares worth $3.96K. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Stone House Investment Management first reported a position in PCRX in Q1 2026 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Stone House Investment Management held 156 shares of Pacira BioSciences worth $3.96K as of Q2 2026.
  • Stone House Investment Management bought 54 Pacira BioSciences shares in Q2 2026, an estimated $1.28K.
  • Pacira BioSciences made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #608 holding.
  • Stone House Investment Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 2 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.